| DOI | Resolve DOI: https://doi.org/10.2174/157340606776056214 |
|---|
| Author | Search for: Kluczyk, A.1; Search for: Kiyota, T.1; Search for: Lazar, C.1; Search for: Popek, T.1; Search for: Roman, G.1; Search for: Konishi, Y.1 |
|---|
| Affiliation | - National Research Council of Canada. NRC Biotechnology Research Institute
|
|---|
| Format | Text, Article |
|---|
| Subject | Chimera method; drug design; drug library; pharmaceutical; scaffold; para-aminobenzoic acid; building blocks; drug evolution; 4-aminobenzoic acid; binding sites; chemistry, pharmaceutical; chimera; combinatorial chemistry techniques; drug design; drug evaluation, preclinical; salicylic acid; structure-activity relationship |
|---|
| Abstract | The drug evolution method represents a novel approach towards efficient rational drug design by implementing the drug evolution concept to the creation and development of general chemical libraries with the purpose of allowing the identification of drug candidates with improved odds and lesser costs than the traditional drug design strategies. As another example of successful translation of the biological evolution into chemical evolution, the chimera method comprises the grafting of selected building blocks, identified through a basic search within a drug library, onto the same substitution sites on a rationally chosen scaffold. The method allows the creation of a library containing both drugs and prospective drug candidates without any priorly required knowledge on the pursued disease or molecular target. Two libraries having scaffolds derived from para-aminobenzoic acid and salicylic acid have exemplified the application of the chimera method. The validation of the method has been achieved through the high number of recognized drugs within the library, which exhibit in the same time a wide variety of therapeutic activities and interact with a broad spectrum of molecular targets. The drug -enriched chimera libraries are expected to provide a highly efficient access to novel drug candidates whose unspecified therapeutic effects should be further revealed through high-throughput screening. |
|---|
| Publication date | 2006-03-01 |
|---|
| Publisher | Bentham Science Publishers |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Identifier | 20852708 |
|---|
| NRC number | NRC-BRI-47487 |
|---|
| NPARC number | 3539192 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | a3cdce56-7c86-4938-9fb3-a47d028f93a0 |
|---|
| Record created | 2009-03-01 |
|---|
| Record modified | 2020-04-22 |
|---|
